Safety of the direct-acting anticoagulants in patients with atrial fibrillation: A meta-analysis

Thrombosis Research

Volumn 135, Issue 6, 2015, Pages 1117-1123

  Rong, Fen ^a   Jia, Bin ^b   Huang, Pinxian ^a   Lynn, Henry S ^b   Zhang, Wei ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

DOACs; Meta analysis; Safety; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; DIRECT ACTING ORAL ANTICOAGULANT; EDOXABAN; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; AGED; CLINICAL TRIAL (TOPIC); FEMALE; HEMORRHAGE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; RISK; RISK FACTOR; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; RISK; RISK FACTORS; STROKE; WARFARIN;

EID: 84929515231     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.004     Document Type: Article

References (39)

1. V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 e101 e198
2. Gene R. Quinn, Daniel E. Singer, Yuchiao Chang, Alan S. Go, Leila H. Borowsky, and Natalia Udaltsova Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin Am. J. Cardiol. 4 2014 583 586
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
4. Christian T. Ruff, Robert P. Giugliano, Eugene Braunwald, Elaine B. Hoffman, Naveen Deenadayalu, and Michael D. Ezekowitz Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 9921 2014 955 962
5. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
6. J.P. Piccini, R.D. Lopes, and K.W. Mahaffey Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation Curr Opin Cardiol 25 2010 312 320
7. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
8. Y.Y. Lam, T.K.W. Ma, and B.P. Yan Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation Int J Cardiol 150 2011 4 11
9. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
10. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
11. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, and J.L. Halperin Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
12. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
13. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
14. A. Liew, J.W. Eikelboom, and M. O'Donnell Extended-duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: a meta-analysis of the randomized controlled trials J Thromb Haemost 12 2014 107 109
15. C.S. Miller, S.M. Grandi, A. Shimony, K.B. Filion, and M.J. Eisenberg Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am J Cardiol 110 2012 453 460
16. D. Capodanno, P. Capranzano, G. Giacchi, V. Calvi, and C. Tamburino Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients Int J Cardiol 167 2013 1237 1241
17. Bin Jia, Henry S. Lynn, Fen Rong, and Wei Zhang Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation J Cardiovasc Pharmacol 64 2014 368 374
18. M. Hori, M. Matsumoto, N. Tanahashi, S.I. Momomura, S. Uchiyama, and S. Goto Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation Circ J 76 2012 2104 2111
19. C. Van Walraven, A. Jennings, N. Oake, D. Fergusson, and A.J. Forster Effect of study setting on anticoagulation control: a systemic review and meta regression Chest 129 2006 1155 1166
20. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, and J.P. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e 1000100
21. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
22. M. Keisu, and T.B. Andersson Drug-induced liver injury in humans: the case of ximelagatran Handb Exp Pharmacol 196 2010 407 418
23. S. Apostolakis, and G.Y. Lip Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban Expert Opin Investig Drugs 21 2012 1057 1064
24. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011
25. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
26. M.D. Ezekowite, S. Connolly, A. Parckh, P.A. Reilly, J. Varrone, and S. Wang Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
27. J.E. Strobeck Stroke prevention in atrial fibrillation: managing the risks in light of New oral anticoagulants Cardiovasc Drugs Ther 26 2012 331 338
28. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
29. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort Stroke 41 2010 2731 2738
30. G.Y. Lip, L. Frison, J.L. Halperin, and D.A. Lane Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
31. Jan Beyer-Westendorf, Vera Gelbricht, Kati Förster, Franziska Ebertz, Denise Röllig, and Thomas Schreier Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry Br J Clin Pharmacol 78 4 2014 908 917
32. S.J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of establishing new antithrombotic therapies in atrial fibrillation Circulation 116 2007 449 455
33. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during Antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 1996 409 416
34. W. Ng, W.M. Wong, W.H. Chen, H.F. Tse, P.Y. Lee, and K.C. Lai Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease World J Gastroenterol 12 2006 2923 2927
35. United States Food and Drug Administration FDA approves Pradaxa to prevent stroke in people with atrial fibrillation Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm23024.htm
36. United States Food and Drug Administration FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm
37. Francesco Dentali, Nicoletta Riva, Mark Crowther, Alexander G.G. Turpie, Gregory Y.H. Lip, and Walter Ageno Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature Circulation 126 2012 2381 2391
38. K.P. Cabral, J. Ansell, and E.M. Hylek Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification J Thromb Haemost 9 2011 441 449
39. C.L. Morgan, P. McEwan, A. Tukiendorf, P.A. Robinson, A. Clemens, and J.M. Plumb Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control Thromb Res 124 2009 37 41